137 related articles for article (PubMed ID: 7603139)
1. Control of group C meningococcal disease in Australian aboriginal children by mass rifampicin chemoprophylaxis and vaccination.
Pearce MC; Sheridan JW; Jones DM; Lawrence GW; Murphy DM; Masutti B; McCosker C; Douglas V; George D; O'Keefe A
Lancet; 1995 Jul; 346(8966):20-3. PubMed ID: 7603139
[TBL] [Abstract][Full Text] [Related]
2. Epidemic meningococcal meningitis in central Australia, 1987-1991.
Patel MS; Merianos A; Hanna JN; Vartto K; Tait P; Morey F; Jayathissa S
Med J Aust; 1993 Mar; 158(5):336-40. PubMed ID: 7605395
[TBL] [Abstract][Full Text] [Related]
3. Outbreak of group C meningococcal disease in Australian Aboriginal children.
Booy R
Lancet; 1995 Aug; 346(8974):572-3. PubMed ID: 7658793
[No Abstract] [Full Text] [Related]
4. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
Noronha CP; Struchiner CJ; Halloran ME
Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
[TBL] [Abstract][Full Text] [Related]
5. Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine.
Masterton RG; Youngs ER; Wardle JC; Croft KF; Jones DM
J Infect; 1988 Sep; 17(2):177-82. PubMed ID: 3141518
[TBL] [Abstract][Full Text] [Related]
6. Outbreak of group C meningococcal disease in Australian Aboriginal children.
Holmes W
Lancet; 1995 Aug; 346(8974):573-4. PubMed ID: 7658794
[No Abstract] [Full Text] [Related]
7. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
[TBL] [Abstract][Full Text] [Related]
8. Effect of group-A meningococcal vaccine in army recruits in Finland.
Mäkelä PH; Käyhty H; Weckström P; Sivonen A; Renkonen OV
Lancet; 1975 Nov; 2(7941):883-6. PubMed ID: 53370
[TBL] [Abstract][Full Text] [Related]
9. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
Sante; 1997; 7(6):384-90. PubMed ID: 9503496
[TBL] [Abstract][Full Text] [Related]
10. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria.
Mohammed I; Obineche EN; Onyemelukwe GC; Zaruba K
J Infect; 1984 Sep; 9(2):190-6. PubMed ID: 6438244
[TBL] [Abstract][Full Text] [Related]
11. Control of meningococcal infection in the African meningitis belt by selective vaccination.
Greenwood BM; Wali SS
Lancet; 1980 Apr; 1(8171):729-32. PubMed ID: 6103155
[TBL] [Abstract][Full Text] [Related]
12. Control of epidemic meningococcal meningitis by mass vaccination.
Mohammed I; Zaruba K
Lancet; 1981 Jul; 2(8237):80-2. PubMed ID: 6113451
[No Abstract] [Full Text] [Related]
13. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
[TBL] [Abstract][Full Text] [Related]
14. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.
Erwa HH; Haseeb MA; Idris AA; Lapeyssonnie L; Sanborn WR; Sippel JE
Bull World Health Organ; 1973; 49(3):301-5. PubMed ID: 4211056
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
16. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the use of mass chemoprophylaxis during a school outbreak of enzyme type 5 serogroup B meningococcal disease.
Jackson LA; Alexander ER; DeBolt CA; Swenson PD; Boase J; McDowell MG; Reeves MW; Wenger JD
Pediatr Infect Dis J; 1996 Nov; 15(11):992-8. PubMed ID: 8933547
[TBL] [Abstract][Full Text] [Related]
18. [Meningococcal disease in the Netherlands: media hype, but not an epidemic].
van Furth AM; Zaaijer HL
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168
[TBL] [Abstract][Full Text] [Related]
19. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
Wahdan MH; Sallam SA; Hassan MN; Abdel Gawad A; Rakha AS; Sippel JE; Hablas R; Sanborn WR; Kassem NM; Riad SM; Cvjetanović B
Bull World Health Organ; 1977; 55(6):645-51. PubMed ID: 413639
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
